The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Using New Retinal Imaging Technologies To Improve Treatment And Classification Of Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$227,644.00
Summary
Diabetic retinopathy is the leading cause of blindness in Australia. This project aims to use new ways of imaging changes in the back of the eye to try to improve the treatment and diagnosis of diabetic retinopathy.
The Influence Of Aqueous And Plasma Cytokines In Treatment Outcomes For Diabetic Macular Oedema
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Diabetic macular oedema (DME) is the commonest cause of central visual loss in diabetics and has been linked to increased levels of vascular endothelial growth factor (VEGF) in the eye. DME is treated with anti-VEGF injections, but these need to be repeated, with some patients failing to respond. We plan to see if levels of VEGF and other inflammatory markers will predict treatment response, so those unlikely to respond can be spared futile treatment and receive alternative treatment earlier.
Regulation Of Bone Marrow Progenitor Cells For Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$442,930.00
Summary
Diabetic retinopathy (DR) is the leading cause of blindness in the working population of developed countries. Current treatments cannot restore the retinal vascular damage in DR. This project intends to combat DR by repairing the damaged retinal vasculature through short- and long-term regulations of the function of bone marrow derived endothelial progenitor cells. Success in this project would potentially have a major impact on all diabetic vascular complications.
Low Cost Smart Screening System For Sight Threatening Eye Disease: Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$529,079.00
Summary
The aim of the project is to develop an automated disease grading and clinical decision support system for diabetic retinopathy (DR) to perform eye screening by primary care providers and nurses. The grading system will automatically extract DR pathology from a patient’s color fundus images by image processing, feature detection and machine learning algorithms. Based on the detected information, the system can classify the patient as non symptom or a specific disease level.
Novel Functional Testing For Early Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$447,578.00
Summary
About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in t ....About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in treatment.Read moreRead less
Molecular Genetic Risk Factors And Mechanisms In Blinding Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
This project aims to understand the genetic causes of blinding eye diseases. We have recently identified genetic variation that contributes to the risk of glaucoma and diabetic eye disease. We are exploring the mechanisms through which this leads to disease by looking at differences in the genes in patients with disease compared to unaffected individuals. We hope to be able to identify genes that could be the target of new therapies to prevent blindness and visual impairment in the community.
Epidemiological And Molecular Risk Factors For Diabetic Retinopathy Blindness.
Funder
National Health and Medical Research Council
Funding Amount
$61,988.00
Summary
Diabetic retinopathy (DR) is the leading cause of blindness in working age adults, affecting 30% of Australians with diabetes. Patients at most risk of blindness are the focus of this project. We aim to (1) investigate why some people are more likely to develop blinding DR by looking at genetic difference between diabetic patients with and without DR; and, (2) help to understand why Indigenous Australians are so over represented in this subset of diabetic patients going blind from DR.
Nanoparticle-based Anti-VEGF Treatment For Ocular Neovascularization
Funder
National Health and Medical Research Council
Funding Amount
$576,921.00
Summary
Diseases like AMD and DR are the leading cause for substantial and irreversible vision loss as a direct effect of pathologic ocular neovascularization and have a significant economic impact on individuals, families, health systems and countries. Nowadays, the treatment requires frequent intravitreal injections of anti-VEGF antibody with all the risks of an invasive intraocular procedure. Nanotechonoly-based drug delivery system will provide a less invasive treatment for this kind of disease.
A Bench To Bedside Approach To Improving Treatment Of Blinding Retinal Diseases
Funder
National Health and Medical Research Council
Funding Amount
$452,051.00
Summary
I am a retinal specialist and clinician scientist directing a group dedicated to identifying improved treatments for blinding macular disease. My clinical research unit conducts randomised clinical trials and pioneered the use of intraocular steroid therapy. My Laboratory research group is interested in stem cell therapy, proteomic analysis of macular disease and the role of Muller cell dysfunction in retinal vascular disease.
Mechanisms Of Retinal Functional Hyperaemia In Humans With And Without Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$117,526.00
Summary
Fenofibrate has been shown to reduce the progression of diabetic retinopathy (DR) in patients with type 2 diabetes by up to 40%, however the mechanisms behind this result are poorly understood. This research will investigate measures of local and systemic endothelial dysfunction and levels of lipids and lipoproteins to determine how fenofibrate affects the progression of DR in patients with type 2 diabetes and in doing so form the basis of further basic and clinical research.